Matrix Drug Screen Identifies Synergistic Drug Combinations to Augment SMAC Mimetic Activity in Ovarian Cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Inhibitor of apoptosis (IAP) proteins are upregulated in ovarian cancer, promoting tumor cell survival.
• Birinapant, a SMAC mimetic, targets IAPs to restore apoptosis but shows limited efficacy as a single agent in recurrent ovarian cancer.
• Developing combination therapies is crucial to overcome resistance and improve treatment outcomes.

Purpose of the Study:

• To identify synergistic drug combinations with birinapant for recurrent ovarian cancer.
• To evaluate the efficacy and underlying mechanisms of the birinapant plus docetaxel combination.
• To provide a rationale for clinical trials of this combination therapy.

Main Methods:

• High-throughput drug screening to identify synergistic combinations with birinapant.
• In vitro and in vivo studies to assess the efficacy of birinapant plus docetaxel.
• Mechanistic studies investigating caspase activation, TNF-α upregulation, NF-kB signaling, and microtubule stabilization.

Main Results:

• Birinapant plus docetaxel demonstrated remarkable synergy in preclinical models of ovarian cancer.
• The combination enhanced caspase activation and induced docetaxel-mediated TNF-α upregulation.
• Synergistic effects involved alternative NF-kB signaling and birinapant-induced microtubule stabilization.

Conclusions:

• The combination of birinapant and docetaxel exhibits significant preclinical synergy against recurrent ovarian cancer.
• Convergent molecular pathways underpin the enhanced anti-tumor activity of this combination.
• Birinapant plus docetaxel warrants further investigation in Phase 2 clinical trials for recurrent ovarian cancer.